Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib versus pegylated interferon α-2b alone for treating hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.
Epistemonikos ID: 44c14656fe0bc87329dd1978995da14af62ac07b
First added on: Feb 19, 2024